0001161697-23-000243.txt : 20230407 0001161697-23-000243.hdr.sgml : 20230407 20230407170021 ACCESSION NUMBER: 0001161697-23-000243 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230405 FILED AS OF DATE: 20230407 DATE AS OF CHANGE: 20230407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tierney David S CENTRAL INDEX KEY: 0001292636 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 23809161 MAIL ADDRESS: STREET 1: C/O ABLE LABORATORIES, INC. STREET 2: 6 HOLLYWOOD COURT, CN 1013 CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 4 1 form4.xml FORM 4 FOR 04-05-2023 X0407 4 2023-04-05 0 0001369568 CATALYST PHARMACEUTICALS, INC. CPRX 0001292636 Tierney David S 355 ALHAMBRA CIRCLE, SUITE 801 CORAL GABLES FL 33134 1 0 0 0 0 Common stock, par value $0.001 per share 2023-04-05 4 M 0 30000 0.79 A 343541 D Common stock, par value $0.001 per share 2023-04-05 4 S 0 30000 16.83 D 313541 D Options to purchase common stock 0.79 2023-04-05 4 M 0 30000 0 D 2023-06-15 Common Stock 30000 280500 D Dr. Tierney has advised the Company that the sale of shares was to pay the exercise price of the shares and to raise funds for personal reasons, and does not relate to any disagreements between Dr. Tierney and the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company. Shares were sold in various lots from $16.70 to $16.98 per share. The listed sales price represents a weighted average price for the shares sold. The option was granted on June 15, 2016 and previously vested in two annual installments. /s/ David S. Tierney 2023-04-07